NCT00385450

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor in the Perioperative Period

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period. This study will investigate whether or not Nelfinavir increases those CD4 counts in the post-operative period.

Detailed description

See Brief Summary.

Conditions

• Cardiopulmonary Bypass

Interventions

Type	Name	Description
DRUG	Nelfinavir/placebo	1250mg/twice each day/four days.

Timeline

• Start date: 2006-10-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2006-10-09
• Last updated: 2015-04-28

Locations

1 site across 1 country: United States